Jersey City, NJ-The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases.
Related Content:
Commercial real estate and your practice, part two with Colin Carr
Cleveland Clinic breaks ground on expansion of Cole Eye Institute
The sword and shield of investing
